Acrivon Therapeutics (ACRV) Competitors $6.07 +0.28 (+4.84%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$6.04 -0.03 (-0.41%) As of 01/31/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ACRV vs. DNA, LENZ, PLRX, IMTX, VERV, OPT, ABUS, BCAX, CRGX, and DNTHShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Ginkgo Bioworks (DNA), LENZ Therapeutics (LENZ), Pliant Therapeutics (PLRX), Immatics (IMTX), Verve Therapeutics (VERV), Opthea (OPT), Arbutus Biopharma (ABUS), Bicara Therapeutics (BCAX), CARGO Therapeutics (CRGX), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Ginkgo Bioworks LENZ Therapeutics Pliant Therapeutics Immatics Verve Therapeutics Opthea Arbutus Biopharma Bicara Therapeutics CARGO Therapeutics Dianthus Therapeutics Ginkgo Bioworks (NYSE:DNA) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Is DNA or ACRV more profitable? Acrivon Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Acrivon Therapeutics' return on equity of -47.95% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-298.78% -58.54% -34.24% Acrivon Therapeutics N/A -47.95%-43.73% Do insiders and institutionals believe in DNA or ACRV? 78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to DNA or ACRV? In the previous week, Acrivon Therapeutics had 3 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 10 mentions for Acrivon Therapeutics and 7 mentions for Ginkgo Bioworks. Acrivon Therapeutics' average media sentiment score of 0.38 beat Ginkgo Bioworks' score of 0.35 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in DNA or ACRV? Acrivon Therapeutics received 11 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 97.22% of users gave Acrivon Therapeutics an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformGinkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Acrivon TherapeuticsOutperform Votes3597.22% Underperform Votes12.78% Do analysts recommend DNA or ACRV? Ginkgo Bioworks currently has a consensus target price of $4.58, suggesting a potential downside of 65.72%. Acrivon Therapeutics has a consensus target price of $23.67, suggesting a potential upside of 289.90%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, DNA or ACRV? Acrivon Therapeutics has lower revenue, but higher earnings than Ginkgo Bioworks. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$251.46M3.05-$892.87M-$13.08-1.02Acrivon TherapeuticsN/AN/A-$60.39M-$2.70-2.25 Which has more risk & volatility, DNA or ACRV? Ginkgo Bioworks has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. SummaryAcrivon Therapeutics beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.81M$6.91B$5.59B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.3057.1113.81Price / SalesN/A321.061,261.0581.64Price / CashN/A73.5045.9637.70Price / Book1.135.275.124.71Net Income-$60.39M$136.98M$111.17M$224.24M7 Day Performance11.38%-0.59%2.37%-0.17%1 Month Performance0.83%0.18%3.19%0.60%1 Year Performance57.25%7.68%24.69%20.43% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics1.697 of 5 stars$6.07+4.8%$23.67+289.9%+66.3%$172.81MN/A0.0058Analyst ForecastShort Interest ↑News CoverageDNAGinkgo Bioworks0.6449 of 5 stars$11.84-7.7%$4.58-61.4%N/A$680.49M$217.11M-0.911,218News CoverageLENZLENZ Therapeutics1.9687 of 5 stars$24.67+0.5%$35.40+43.5%N/A$678.45MN/A0.00110Upcoming EarningsAnalyst RevisionNews CoveragePLRXPliant Therapeutics3.9017 of 5 stars$11.00+0.7%$40.50+268.2%-40.0%$669.35M$1.58M-3.2990IMTXImmatics1.446 of 5 stars$5.51-1.6%$16.67+202.5%-51.8%$657.67M$58.44M-8.35260Short Interest ↑VERVVerve Therapeutics2.2935 of 5 stars$7.76-1.9%$25.75+231.8%-29.7%$656.96M$11.76M-3.15110OPTOpthea2.7031 of 5 stars$4.77-2.5%$12.00+151.6%+105.2%$650.77M$120,000.000.008Analyst ForecastShort Interest ↑News CoverageGap UpHigh Trading VolumeABUSArbutus Biopharma2.7053 of 5 stars$3.43+3.3%$5.50+60.3%+40.5%$649.95M$18.14M-7.9890Positive NewsBCAXBicara TherapeuticsN/A$11.65+0.3%$43.75+275.5%N/A$633.99MN/A0.0032Gap UpCRGXCARGO Therapeutics2.7599 of 5 stars$13.66+1.5%$31.80+132.8%-83.6%$628.77MN/A-3.21116Analyst DowngradeAnalyst RevisionNews CoverageDNTHDianthus Therapeutics1.9478 of 5 stars$21.10-0.5%$46.43+120.0%+16.6%$624.56M$2.83M-8.4480Short Interest ↑ Related Companies and Tools Related Companies Ginkgo Bioworks Competitors LENZ Therapeutics Competitors Pliant Therapeutics Competitors Immatics Competitors Verve Therapeutics Competitors Opthea Competitors Arbutus Biopharma Competitors Bicara Therapeutics Competitors CARGO Therapeutics Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRV) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts